Research that won the 10th Bioindustry AwardOn July 15, 2026, Sumitomo Pharma Co., Ltd. and RACTHERA Inc. announced that the ...

Agenus Inc. has surged >195% YTD, driven by optimism around its BOT/BAL combo therapy for MSS colon cancer. Read more on AGEN ...

Summit and AstraZeneca have entered into an agreement whereby AstraZeneca will make an equity investment of $2.0 billion in convertible preferred shares. At the conversion ratio, the investment ...

As you enter your 40s, the type of nutrients your body needs shifts. Adding supplements like vitamin D and B vitamins can ...

Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line ...

Lung02 Phase 3 trial evaluating the efficacy and safety of ifinatamab deruxtecan versus treatment of physician’s choice of chemotherapy (amrubicin, lurbinectedin or topotecan) in patients with ...

AstraZeneca Puts $2 Billion Behind Summit's Ivonescimab, Pairing the PD-1/VEGF Bispecific With Its ADC Portfolio / ADC, Akeso ...

Global Urothelial Cancer Drugs Market was valued at USD 4.03 Billion in 2025 and is expected to grow at 11.34% CAGR to reach USD 11.81 Billion by 2035.

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...

Over a month after Hayden Panettiere’s tragic death at 36, her ex Wladimir Klitschko has filed for a temporary guardianship ...

Bengaluru: The US Food and Drug Administration has approved AbbVie's drug for Parkinson's disease in adults, the health ...

Chronic pancreatitis is characterised by complex, multifactorial pain affecting 80–90% of patients. Pain arises from overlapping nociceptive and neuropathic mechanisms, often accompanied by CNS ...